Date of preparation April 2014 │BRI001081 ACC.14 Annual Scientific Sessions of the American College of Cardiology Washington DC 29-31 March 2014
Acc2014 10
Nov 12, 2014
Acc2014 10
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Date of preparation April 2014 │BRI001081
ACC.14Annual Scientific Sessions of the American College of Cardiology
Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
Disclaimer
• AstraZeneca abides by the Medicines Australia Code of Conduct (Edition 17) and AstraZeneca Global Policies, and as such will not engage in the promotion of unregistered products or unapproved indications.
• These highlights have been suggested by a group of cardiologists who attended ACC.14, compiled by an external medical writer and sponsored by AstraZeneca.
• Statements of fact and opinions expressed are those of the speakers individually and, unless expressly stated to the contrary, are not the opinion or position of AstraZeneca. AstraZeneca does not endorse or approve, and assumes no responsibility for, the content, accuracy, or completeness of the information presented. Presentations are intended for educational purposes only and do not replace independent professional judgement.
• Please refer to the appropriate approved Product Information before prescribing any agents mentioned in these highlights.
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Undetectable hs-cTnT allows safe discharge of chest pain patients
Commentary:
Associate Professor Chris ZeitzQueen Elizabeth Hospital, Adelaide
Late-breaking trial
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
39 of 8907 patients with hs-cTnT had MI within 30 days
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
Date of preparation April 2014 │BRI001081
ACC.14Washington DC
29-31 March 2014
• In Australia, chest pain assessment and management consumes significant health care resources.
• Patients clinically assessed as high-risk ACS should be managed as such regardless of troponin level(s).
• Patients clinically assessed as not being high-risk ACS are considered for early discharge unless repeat ECGs and biomarkers change.
• This study shows that the decision to discharge non-high-risk patients can safely be made at a much earlier time point than is currently practised.
• Nevertheless, additional strategies that can identify the very few low-risk patients that will still have adverse events should be considered
Commentary: Associate Professor Chris Zeitz
Related Documents
